Want to see CRDF full AI Analyst Report?
CRDF Stock Chart & Stats
$1.02
$0.02(2.30%)
At close: 4:00 PM EDT
$1.02
$0.02(2.30%)
Day’s Range― - ―
52-Week Range$0.76 - $3.31
Previous CloseN/A
Volume462.43K
Average Volume (3M)751.44K
Market Cap
$84.80M
Enterprise Value$54.85
Total Cash (Recent Filing)$34.52M
Total Debt (Recent Filing)$457.00K
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Oct 29, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding77,795,250
10 Day Avg. Volume655,800
30 Day Avg. Volume751,436
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside488.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.58
Revenue Forecast (FY)$298.71K
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces solvency pressure and leaves the company with greater flexibility than a highly leveraged development-stage biotech. This can help management direct available capital toward clinical programs and limit interest-related constraints while it pursues regulatory progress.
Promising Clinical Pipeline SignalEncouraging Phase 2 data and a stated path toward registration provide the clearest potential catalyst for transforming onvansertib from an R&D asset into a commercially valuable therapy. If validated, this could improve partnering prospects and future monetization.
Recent Funding Extends LiquidityThe completed financing provides near-term capital to continue operations and advance the oncology pipeline without relying immediately on another transaction. That liquidity can support clinical execution over the coming months, although the equity-linked structure creates a shareholder cost.
Bears Say
Pre-commercial Revenue And Severe LossesCardiff has not established a meaningful commercial revenue base, while operating expenses produce losses that are very large relative to sales. This weak earnings profile means future value depends heavily on clinical and regulatory success rather than an established product franchise.
Persistent Cash BurnSustained negative cash generation indicates that Cardiff cannot currently fund its R&D model from internal operations. Continued development therefore depends on capital markets or strategic transactions, creating financing uncertainty and potentially limiting the pace or scope of pipeline investment.
Onvansertib License LitigationA dispute over the license supporting the lead program could affect Cardiff’s ability to continue developing or commercialize onvansertib. Because the pipeline is centered on this asset, unresolved intellectual-property and continuity issues represent a durable risk to the company’s strategic foundation.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $0.76 and its highest was $3.31 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $84.80M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 50 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.02.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 77,795,250 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (488.24% Upside)
$6.00 (488.24% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 37.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
CRDF Stock 12 Month Forecast
Average Price Target
$6.00
▲(488.24% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
2.89% Insiders
6.97% Mutual Funds
9.33% Other Institutional Investors
76.89% Public Companies and
Individual Investors